ReviewLife (Basel, Switzerland)2023
The Role of Intestinal Microbiota in Celiac Disease and Further Therapeutic Perspectives.
Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 14 citations in OpenAlex.
- Combined ProbioticMolecules (Basel, Switzerland) · 2026Trial
- PROBIOTICS AS AN ADJUNCTIVE THERAPY FOR CELIAC DISEASE: SYMPTOM RELIEF AND QUALITY OF LIFE IMPROVEMENT.Arquivos de gastroenterologia · 2025Trial
- FMT from Turkish patients with celiac disease is associated with celiac-like enteropathy features in a rat model.BMC gastroenterology · 2026Article
- Pediatric celiac disease and coexisting immune-mediated conditions: a five-year single-center study from North-Eastern Romania.Frontiers in pediatrics · 2026Article
- Causal Relationship Between Cataracts and Gastrointestinal Diseases: A Two-Sample Mendelian Randomization Study.Translational vision science & technology · 2025Article
- Oxidative Stress, Gut Microbiota, and Extracellular Vesicles: Interconnected Pathways and Therapeutic Potentials.International journal of molecular sciences · 2025Review
- Integrated analysis of fecal microbiota and metabolomics reveals unique characteristics of asymptomatic and classic celiac disease.Frontiers in microbiology · 2025Article
- Potential of nutraceuticals in celiac disease.Tissue barriers · 2025Review
- Special Issue: "Novel Diagnosis and Treatment of Gastrointestinal Disease".Life (Basel, Switzerland) · 2024Article
- Review
- Interactions between Dietary Antioxidants, Dietary Fiber and the Gut Microbiome: Their Putative Role in Inflammation and Cancer.International journal of molecular sciences · 2024Review
- How the Microbiota May Affect Celiac Disease and What We Can Do.Nutrients · 2024Review
- Disruptions of Gut Microbiota are Associated with Cognitive Deficit of Preclinical Alzheimer's Disease: A Cross-Sectional Study.Current Alzheimer research · 2024Article
- The Contribution of the Intestinal Microbiota to the Celiac Disease Pathogenesis along with the Effectiveness of Probiotic Therapy.Microorganisms · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Celiac disease (CD) is an immune-mediated enteropathy caused by exposure to gluten and related prolamins in genetically susceptible individuals. It is a complex genetic disorder with multiple contributing genes. Linkage studies have identified several genomic regions that probably contain CD susceptibility genes. The most important genetic factors are HLA-DQ2 and DQ8. Several known environmental triggers promote the onset of CD at any age after gluten introduction in individuals with a genetic background, such as viral infections and intestinal dysbiosis. Recent publications have described the interference of the intestinal microbiome in gluten metabolism, modulation of local immune reactions, and in maintaining normal gut permeability. These results have promoted further lines of research on the benefit of probiotic administration to prevent disease onset or alleviate clinical symptoms along with a gluten-free diet (GFD). The relationship between gut microbiome changes and the onset of CD is incompletely understood, still being the subject of current research. This narrative review analyzes the interplay between environmental factors, intestinal microbiome alterations, and the course of CD. Furthermore, this review sets out to discuss if modulation of intestinal microflora with pre- and probiotics along with a GFD could represent a reliable therapeutic target for celiac patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.